| Prospective randomized trial of six-month versus nine-month therapy for intestinal tuberculosis. | |
| | |
MedLine Citation:
|
PMID: 19667282 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Intestinal tuberculosis (TB) continues to be a common disease worldwide. However, the optimal duration of anti-TB medication has not been well established. We therefore compared the efficacy of 6-month and 9-month therapy in the treatment of intestinal TB. Ninety patients definitely diagnosed with intestinal TB were randomized into 6-month (n = 45) or 9-month (n = 45) treatment groups, prospectively. The primary end point was complete response, defined as endoscopic healing of active lesions. Patients were followed up monthly for 3 months after therapy initiation, then every 3 months until the end of therapy, and finally 1 year later. Relapse was assessed 1 year after the end of therapy by patient interview and colonoscopy. Baseline characteristics were similar in the 6-month and 9-month groups. Intention-to-treat analysis revealed no significant differences between the two groups in complete response (6-month group, 93.3%; 9-month group, 91.1%; P = 1.00) or recurrence rate (6-month group, 2.4%; 9-month group, 0.0%; P = 1.00). Median follow-up duration was 39 months in the 6-month group and 32 months in the 9-month group. No surgery was performed on any patient in either group. In conclusion, the 6-month therapy was as effective as 9-month therapy in patients with intestinal TB and may have the additional benefits of reduced treatment cost and increased compliance. |
| | |
Authors:
|
Sang Hyoung Park; Suk-Kyun Yang; Dong-Hoon Yang; Kyung Jo Kim; Soon Man Yoon; Jae Won Choe; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Jin-Ho Kim |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2009-08-10 |
Journal Detail:
|
Title: Antimicrobial agents and chemotherapy Volume: 53 ISSN: 1098-6596 ISO Abbreviation: Antimicrob. Agents Chemother. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-09-22 Completed Date: 2009-12-14 Revised Date: 2010-09-27 |
Medline Journal Info:
|
Nlm Unique ID: 0315061 Medline TA: Antimicrob Agents Chemother Country: United States |
Other Details:
|
Languages: eng Pagination: 4167-71 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antitubercular Agents / therapeutic use* Ethambutol / therapeutic use Female Humans Isoniazid / therapeutic use Male Middle Aged Pyrazinamide / therapeutic use Rifampin / therapeutic use Treatment Outcome Tuberculosis, Gastrointestinal / drug therapy* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antitubercular Agents; 13292-46-1/Rifampin; 54-85-3/Isoniazid; 74-55-5/Ethambutol; 98-96-4/Pyrazinamide |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in ...
Next Document: Pharmacokinetics of Fosamprenavir plus Ritonavir in HIV-1-infected Adult Subjects with Hepatic Impai...